Airway product recalls weigh down on CareFusion and Smiths
This article was originally published in Clinica
Executive Summary
The US FDA has given CareFusion's recall of its Avea ventilator the most serious classification. The company initiated the Class I action in September when it discovered a potential defect in the ventilator that could cause it to activate a false alarm and stop ventilating, which, in turn, could lead to patient injury or death if left unnoticed. Devices affected by the recall were manufactured between 1 March 2009 and 30 June 2011.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.